Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials

Contemporary Clinical Trials

Volumn 33, Issue 5, 2012, Pages 949-958

  Chen, Zhengjia ^a   Tighiouart, Mourad ^b   Kowalski, Jeanne ^a  

^a EMORY UNIVERSITY   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Escalation with overdose control; Maximum tolerated dose; Multiple toxicities; Normalized equivalent toxicity score; Quasi continuous; Toxicity score system

Indexed keywords

ACCURACY; ARTICLE; BAYES THEOREM; CANCER RESEARCH; DRUG EFFECT; DRUG OVERDOSE; DRUG TOXICITY; ESCALATION WITH OVERDOSE CONTROL; HUMAN; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL (TOPIC); SCORING SYSTEM; SIMULATION;

ALGORITHMS; ANTINEOPLASTIC AGENTS; BAYES THEOREM; CLINICAL TRIALS, PHASE I AS TOPIC; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG OVERDOSE; HUMANS; LIKELIHOOD FUNCTIONS; MAXIMUM TOLERATED DOSE; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84864313283     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2012.04.007     Document Type: Article

References (27)

1. Lonial S., Kaufman J., Tighiouart M., Nooka A., Langston A.A., Heffner L.T., et al. A Phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clin Cancer Res 2010, 16:5079-5086.
2. Sinha R., Kaufman J.L., Khoury H.J., King N., Shenoy P.J., Lewis C., et al. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. Cancer 2012, 10.1002/cncr.26660.
3. Borghaei H., Alpaugh K., Hedlund G., Forsberg G., Langer C., Rogatko A., et al. Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:4116-4123.
4. Cheng J.D., Babb J.S., Langer C., Aamdal S., Robert F., Engelhardt L.R., et al. Individualized patient dosing in phase I clinical trials: the role of EWOC in PNU-214936. J Clin Oncol 2004, 22:602-609.
5. Potter D. Phase I. studies of chemotherapeutic agents in cancer patients: a review of the designs. J Biopharm Stat 2006, 16:579-604.
6. National Cancer Institute Common Toxicity Criteria for Adverse Events v3.0 (CTCAE) 2003, http://ctep.cancer.gov/reporting/ctc.html.
7. Babb J., Rogatko A., Zacks S. Cancer Phase I clinical Trials: efficient dose escalation with overdose control. Stat Med 1998, 17:1103-1120.
8. Tighiouart M., Rogatko A., Babb J.S. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control. Stat Med 2005, 24:2183-2196.
9. Tighiouart M., Rogatko A. Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials. Stat Sci 2010, 25:217-226.
10. Chen Z.J., Krailo M.D., Azen S.P., Tighiouart M. A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in Phase I clinical trials. Contemp Clin Trials 2010, 31:473-482.
11. Gourieroux C., Monfort A., Trognon A. Pseudo maximum likelihood methods: theory. Econometrica 1984, 52:681-700.
12. McCullagh P., Nelder J. Generalized Linear Models 1989, Chapman and Hall, New York. 2nd ed.
13. Yuan Z., Chappell R., Bailey H. The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach. Biometrics 2007, 63:173-179.
14. Zacks S., Rogatko A., Babb J. Optimal Bayesian-feasibile dose escalation for cancer phase I trials. Stat Probab Lett 1998, 38:215-220.
15. Chu P.L., Lin Y., Shih W.J. Unifying CRM and EWOC designs for phase I cancer clinical trials. J Stat Plann Infer 2009, 139:1146-1163.
16. Schilder R.J., Gallo J.M., Millenson M.M., Bookman M.A., Weiner L.M., Rogatko A., et al. Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy. J Clin Oncol 2001, 19:1183-1194.
17. Freedman G.M., Meropol N.J., Sigurdson E.R., Hoffman J., Callahan E., Price R., et al. Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2007, 67:1389-1393.
18. Carota C., Parmigiani G. Semiparametric regression for count data. Biometrika 2002, 89:265-281.
19. Gordon N.H., Willson J.K. Using toxicity grades in the design and analysis of cancer phase I clinical trials. Stat Med 1992, 11:2063-2075.
20. Wang C., Chen T., Tyan I. Designs for phase I cancer clinical trials with differentiation of graded toxicity. Transplant Proc 2000, 29:975-987.
21. Potthoff R.F., George S.L. Flexible Phase I clinical trials: allowing for nonbinary toxicity response and removal of other common limitations. Stat Biopharm Res 2009, 1:213-228.
22. Bekele B.N., Thall P. Dose-finding based on multiple toxicities in a soft tissue sarcoma trial. J Am Stat Assoc 2004, 99:26-35.
23. Bekele B., Thall P. Dose-finding based on multiple ordinal toxicities in Phase I oncology Trials. Statistical Methods for Dose-Finding Experiments Chichester 2006, 243-258. Wiley, UK. S. Chevret, W. Sussex (Eds.).
24. Bekele B.N., Li Y., Ji Y. Risk-group-specific dose finding based on an average toxicity score. Biometrics 2010, 66:541-548.
25. Rogatko A., Babb J.S., Wang H., Slifker M.J., Hudes G.R. Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials. Clin Cancer Res 2004, 10:4645-4651.
26. Babb J.S., Rogatko A. Patient specific dosing in a cancer phase I clinical trial. Stat Med 2001, 20:2079-2090.
27. Tighiouart M., Rogatko A., Xu Z. Incorporating patient's characteristics in cancer phase I clinical trials using escalation with overdose control. Joint Statistical Meetings. Salt Lake City, Utah 2007.